Cantor Fitzgerald Brokers Boost Earnings Estimates for SLDB

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2025 earnings estimates for Solid Biosciences in a note issued to investors on Wednesday, February 19th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will post earnings per share of ($1.43) for the year, up from their prior estimate of ($2.45). The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share.

Other analysts have also recently issued research reports about the stock. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Solid Biosciences in a report on Friday, January 10th. JPMorgan Chase & Co. cut their price objective on shares of Solid Biosciences from $15.00 to $12.00 and set an "overweight" rating on the stock in a report on Tuesday, November 12th. JMP Securities started coverage on shares of Solid Biosciences in a report on Tuesday, December 10th. They set an "outperform" rating and a $15.00 price objective on the stock. Wedbush started coverage on shares of Solid Biosciences in a report on Friday, December 13th. They issued an "outperform" rating and a $16.00 target price on the stock. Finally, Citizens Jmp raised shares of Solid Biosciences to a "strong-buy" rating in a report on Tuesday, December 10th. Nine analysts have rated the stock with a buy rating and four have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $15.40.

Solid Biosciences Trading Down 3.7 %

SLDB stock opened at $5.78 on Friday. Solid Biosciences has a twelve month low of $2.88 and a twelve month high of $15.05. The company's 50 day moving average is $3.83 and its two-hundred day moving average is $5.76. The stock has a market cap of $234.55 million, a P/E ratio of -1.90 and a beta of 2.01.

Hedge Funds Weigh In On Solid Biosciences

Several institutional investors have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Solid Biosciences during the 4th quarter worth $34,000. Corton Capital Inc. purchased a new stake in shares of Solid Biosciences during the 4th quarter worth $41,000. Invesco Ltd. purchased a new stake in shares of Solid Biosciences during the 4th quarter worth $49,000. Sei Investments Co. purchased a new stake in shares of Solid Biosciences during the 4th quarter worth $52,000. Finally, Wells Fargo & Company MN boosted its position in shares of Solid Biosciences by 29.4% during the 4th quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock worth $53,000 after purchasing an additional 2,986 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Solid Biosciences

In other Solid Biosciences news, COO David T. Howton sold 5,072 shares of the business's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total value of $28,403.20. Following the transaction, the chief operating officer now directly owns 15,663 shares of the company's stock, valued at approximately $87,712.80. The trade was a 24.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Alexander Cumbo sold 11,114 shares of the business's stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $5.60, for a total transaction of $62,238.40. Following the completion of the transaction, the chief executive officer now directly owns 38,484 shares in the company, valued at $215,510.40. This represents a 22.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,069 shares of company stock valued at $137,301. 13.63% of the stock is owned by company insiders.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.